NCT04403139View on ClinicalTrials.gov

VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 27, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Varicella Zoster Virus Infection
Interventions
DRUG

Shingrix

All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.

Trial Locations (1)

98104

University of Washington Virology Research Clinic, Seattle

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Washington

OTHER